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Aim To develop and do an initial validation of a new simple 
tool (self-administered questionnaire) that would be sensi-
tive and specific enough to detect early changes in smokers 
leading to future development of chronic obstructive pul-
monary disease (COPD).
Methods 224 consecutive participants (50.9% women), with 
mean ± standard deviation age of 52.3 ± 6.7 years, 37.5 ± 16.7 
pack-years smoking history (85.8% active smokers), and no 
prior diagnosis of COPD were recruited. The MARKO ques-
tionnaire was self-administered twice; at the general practi-
tioner’s office and after 2-4 weeks at the tertiary care hospi-
tal. Participants were assessed for COPD by a pulmonologist 
after filling in a quality of life (QoL) questionnaires, history-
taking, physical examination, lung function test, 6-minute 
walk test, and laboratory tests. They were divided into four 
subgroups: “healthy” smokers, symptomatic smokers, and 
smokers with mild and moderately severe COPD.
Results Psychometric analyses indicated that the 18-item 
questionnaire had a very good internal consistency (Cron-
bach’s alpha = 0.91) and test-retest reliability for a four week 
period (ρc = 0.89, 95% confidence interval [CI] 0.85-0.92, Lin’s 
concordance). A significant correlations of MARKO scores 
were found with two QoL questionnaires; r = 0.69 (P < 0.001) 
and r = 0.81 (P < 0.001). Receiver operating characteristic 
curve analysis showed an area under the curve of 0.753 
(95% CI 0.691-0.808, P < 0.001), with a sensitivity of 71.83% 
and specificity of 64.24% to discriminate “healthy” smokers 
from other subgroups.
Conclusion Based on psychometric analyses and high con-
vergent validity correlation with already validated QoL ques-
tionnaires, the newly developed MARKO questionnaire was 
shown to be a reliable self-administered short health status 
assessment tool.
Trial registration: Clinicaltrial.gov NCT01550679
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Chronic obstructive pulmonary disease (COPD) is one of the 
major causes of chronic morbidity and mortality through-
out the world (1). Millions of people suffer from this disease 
for years, and die prematurely from it or its complications, 
thus producing a significant impact on the health care sys-
tem and economy. Since COPD is a preventable and treat-
able disease, early detection is very important (1,2). Chronic 
airflow limitation, which is a major characteristic of COPD, is 
caused by a mixture of small airways lesions and parenchy-
ma destruction caused by chronic inflammation. According 
to the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD), to establish the diagnosis, the patient has to have 
a significant exposure, characteristic symptoms, and a sig-
nificant degree of airflow limitation (Tiffeneau index <0.7) 
(1). American Thoracic Society/European Respiratory Soci-
ety (ATS/ERS) use even more stringent criteria for a signifi-
cant airflow limitation based on the lower limit of normal 
(LLN), arguing that using a single point criteria for all age 
groups significantly under- or overestimates the incidence 
and prevalence of COPD in different age groups (3). On the 
other hand, pathophysiological changes, symptoms, and 
diminished health related quality of life (HRQoL) often pre-
cede clinically significant airflow limitation (1). Even though 
cigarette smoking is the major cause of COPD, only a frac-
tion (<1/3) of the smokers develop the disease. Based on 
the recently published data from a subsample (n = 50 008) of 
the UK Biobank, there are significant shared genetic mecha-
nisms underlying airway limitation, COPD, and smoking ad-
diction (4). Despite recommendations for an early diagnosis 
(1,2), up until now, there have been no predictive parame-
ters to evaluate the risk for developing COPD in a particular 
person exposed to tobacco smoke. Interdisciplinary Asso-
ciation for Research in Lung Disease (Associazione Scientifi-
ca Interdisciplinare per lo Studio delle Malattie Respiratorie, 
AIMAR) guidelines recommend using a stepwise approach 
that starts with the screening questionnaire as a first step in 
the identification of a high risk population. Already validat-
ed HRQoL questionnaires like St’ George Respiratory Ques-
tionnaire (SGRQ) or COPD Assessment Test (CAT) have not 
been developed and validated for such a purpose (5,6). The 
aim of our study was to construct, develop, and conduct 
an initial validation of a new simple tool (self-administered 
questionnaire) that would be sensitive and specific enough 
to detect early changes in smokers leading to future devel-
opment of COPD.
MethODS
This study was a part of broader research project “Ear-
ly Detection of COPD Patients in GOLD 0 (Smokers) 
Population – MARKO Project.” The details of the protocol 
of the MARKO project can be found at https://clinicaltri-
als.gov/ct2/show/NCT01550679. The study was approved 
by the Children’s Hospital Srebrnjak Ethics Committee and 
conducted according to the most recent version of the 
Declaration of Helsinki, Good Clinical Practice, and other 
relevant international and national laws. All participants 
signed the Informed consent before starting any proce-
dure related to the study.
Pilot study for understanding/comprehension
A cross-sectional study was conducted in 2009 on a primary 
care level in a large city (Zagreb and surroundings) to assess 
the prevalence of COPD. A subgroup of 138 patients of both 
sexes was chosen based on a previously diagnosed COPD 
for this pilot study. The study was undertaken through 17 
general practitioners’ (GP) offices that possessed the COPD-
6TM pocket screening spirometer (4000 COPD-6TM Respira-
tory Monitor, Vitalograph Ltd, Buckingham, UK).
The GPs were asked to collect the data on all the patients 
who were active smokers with ≥20 pack-years smoking his-
tory and over 40 years of age, irrespective of the reason of 
their visit, about their chronic respiratory conditions includ-
ing COPD, asthma, or any other respiratory condition, respi-
ratory therapy, and exacerbations during the past year. They 
were also asked to measure lung function using the COPD-
6TM (forced expiratory volume in 1 second [FEV1], forced ex-
piratory volume in 6 seconds [FEV6] as a surrogate measure 
for forced vital capacity [FVC], FEV1/FEV6 ratio, and lung age). 
Patients (n = 138) with COPD assessed the readability and 
comprehension of the MARKO questionnaire items. Each of 
the 18 items in MARKO questionnaire was rated on a scale 
from 1-4 (1 meaning lowest level of understanding/compre-
hension and 4 meaning the complete understanding/com-
prehension of each item) (Supplementary material).
Validation study
Participants. The study conducted between 2010-2013 
included 224 consecutive participants (50.9% women) 
with mean ± standard deviation age of 52.3 ± 6.7 years and 
37.5 ± 16.7 pack-years smoking history (85.8% active smok-
ers). They were recruited at 15 GP offices representing an 
equal number of GPs in two major cities (Zagreb and sur-
roundings 7 GPs, Split and surroundings 8 GPs). The partici-
pants were approached by their GPs during a random visit 
to their office (not related to respiratory problems) if they 
were smokers or ex-smokers of the predefined age group. 
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The pre-screening for inclusion/exclusion criteria was con-
ducted through a structured interview. The inclusion crite-
ria were that participants have to have signed the written 
consent; be smokers/ex-smokers of either sex aged 40-65 
years with a smoking history of at least 20 pack-years (cal-
culated as the number of cigarettes smoked per day multi-
plied by the number of years of smoking divided by 20); and 
have no previous diagnosis of COPD. The exclusion criteria 
were any clinically relevant chronic disease (cardiovascular, 
cerebrovascular, diabetes, hepatitis, nephropathy, chronic 
dialysis, systemic disorder, cancer) significantly affecting 
QoL at the time of the first visit; immunosuppressive ther-
apy; preceding acute respiratory disease four weeks before 
the visit; hospitalization for any reason during past three 
months; myocardial infarction, cerebrovascular infarction 
or transient ischemic attack during past six months; diag-
nosis of asthma; and an inability to perform the diagnostic 
protocol. After the diagnostic workup participants were di-
vided into four subgroups defined as “healthy” smokers (no 
respiratory symptoms and FEV1/FVC≥0.7, n = 72), symp-
tomatic smokers (chronic respiratory symptoms as dysp-
nea, cough and/or sputum production and FEV1/FVC≥0.7, 
n = 110), COPD GOLD 1 (chronic respiratory symptoms, 
FEV1/FVC<0.7 and FEV1≥80% predicted, n = 23), and COPD 
GOLD 2 (chronic respiratory symptoms, FEV1/FVC<0.7 and 
FEV1<80% and ≥50% predicted, n = 19) (1).
Measuring instruments
The MARKO questionnaire was constructed and developed 
in the Croatian language for the purpose of this study by 
a group of experts; three medical doctors (pulmonologists 
ŽV, DP, and PMAC) and two psychologists (BRV, AKĐ). It was 
constructed in the Croatian language because the whole 
MARKO study was planned and performed in Croatia and 
did not involve participants from other countries. The 
questionnaire comprised 18 questions covering the mani-
festation and frequency of the symptoms present at the 
early stages of the COPD that could impact the patients’ 
HRQoL. The participants were asked to rate the frequency 
of their symptoms over a designated period of time (eg, 
over past three months for coughing, shortness of breath, 
expectoration, and over past 12 months for pulmonary in-
fections). They also rated their breathing quality and gen-
eral health status. Furthermore, they reported on the short-
ness of breath during daily life activities requiring different 
physical strain, and compared their physical abilities and 
fatigue with respect to their referential age group. The total 
scores ranged from 0 to 57 points, with the higher scores 
indicating poorer HRQoL.
CAT is a validated, short (8-item), and simple self-adminis-
tered questionnaire, with good discriminant properties, de-
veloped for use in routine clinical practice to measure the 
health status of patients with COPD (6). The test was de-
veloped using Rasch analysis as a single dimensional con-
struct. Internal consistency was excellent with Cronbach’s 
α = 0.88 and a good test-retest reliability (intraclass corre-
lation coefficient = 0.8). Every item is rated on a six point 
scale from 0 to 5. Total scores range from 0 (indicating no 
impairment) to 40 (indicating maximum impairment). It is 
openly accessible and available in more than 60 languag-
es. It was validated in 6 different countries using 4 different 
languages and translated to the Croatian language using 
an internationally recommended procedure (7).
SGRQ was designed to measure the overall health sta-
tus and well-being of the patients with obstructive air-
ways disease (5). It is a standardized self-administered 
airways disease-specific questionnaire divided into three 
domains: symptoms (8 items), activity (16 items), and im-
pacts (26 items). Internal consistency (Cronbach’s α) for 
these domains for COPD was 0.61, 0.90, and 0.88, respec-
tively. For each domain and for the overall questionnaire, 
scores range from zero (no impairment) to 100 (maximum 
impairment). The questionnaire is available in more than 
70 languages and openly accessible. SGRQ was not previ-
ously validated for the Croatian language but was translat-
ed using an international recommended procedure and 
used widely in many COPD clinical trials in Croatia (7). The 
SGRQ scores in our study were calculated using score cal-
culation algorithms and missing data imputation (if total 
number of missing items was ≤10) using the Excel® SGRQ 
calculator.
Procedure
The purpose of this initial validation was to understand the 
basic psychometric characteristics of this newly construct-
ed questionnaire and determine how it compares to the al-
ready existing and validated HRQoL questionnaires used for 
COPD, like CAT and SGRQ. Also it was important to under-
stand if the newly developed questionnaire discriminates 
between all 4 subgroups of participants. We also under-
stand that we have different domains and some redundant 
questions as they differ in the level of symptoms severity. 
They were put into the construct on purpose because the 
final evaluation would be made based on the results of par-
ticipants’ follow-up. The main purpose why this question-
naire was developed was to try to pick-up early changes 
in HRQoL that are predictive for the future develop-
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ment of COPD in smokers at risk, or with a progression of 
an early COPD. As there are no up-to-date instruments that 
can be compared with this, the second validation will be 
done using follow-up data that will allow us to discard re-
dundant questions and fully analyze the construct validity 
of MARKO questionnaire. The MARKO questionnaire was 
self-administered twice in a validation study; first at the GP’s 
office and after 2-4 weeks at the tertiary care hospital dur-
ing pulmonologist’s assessment. During the pulmonolo-
gist’s assessment the staff and the participant were blinded 
for the results of MARKO questionnaire obtained at the GP’s 
office. At the tertiary care hospital participants were referred 
to a designated team consisting of a pulmonologist, study 
nurse, and lung function laboratory technician. They filled 
in the self-administered MARKO questionnaire followed by 
CAT and SGRQ, after which they went through a structured 
and predefined diagnostic workup (history-taking, physical 
examination, lung function with bronchodilator test, 6-min-
ute walk test, laboratory tests) to determine the diagnosis 
and staging of their COPD according to the GOLD and were 
divided in four subgroups that were used for further com-
parisons as previously described (1).
Data analyses
Data analyses were conducted using STATISTICA version 12 
(StatSoft, Inc., OK, USA) and MedCalc Statistical Software 
version 15.8 (MedCalc Software bvba, Ostend, Belgium). 
Categorical data are presented as absolute numbers and 
percentages. Quantitative data are expressed as mean and 
standard deviation (SD) or median and interquartile range 
(IQR). Normality of distribution was assessed using Kolm-
ogorov-Smirnov test. Metric characteristics of the MARKO 
questionnaire were analyzed using Cronbach’s alpha, Lin’s 
concordance, and Pearson or Spearman’s correlation coef-
ficients analyzing inner consistency, test-retest reliability, 
and association with other measures of HRQoL and health 
status. Categorical data were compared between groups 
using χ2 test and continuous variables using t test or 
Kruskal-Wallis ANOVA. Discriminative power of the MARKO 
questionnaire was analyzed using receiver operator curve 
(ROC) analysis and presented with area under the curve 
(AUC) (with 95% confidence intervals [CI]) together with 
the associated criterion automatically calculated by statis-
tical software, sensitivity, specificity, and positive (PPV) and 
negative predictive (NPV) values. For the main outcomes, 
logistic regression analysis with odds ratios (ORs) and 95% 
CIs for the 18-item MARKO questionnaire was calculated. 
P < 0.05 was used as significant for all analyses with cor-
rection for multiple comparisons.
ReSuLtS
Pilot study
Results of the pilot study done in 138 COPD patients (52.1% 
women, 54.5 [10.7] years, 35.5 [25.5] pack-years) showed 
that all 18 items of the MARKO questionnaire had a com-
parable comprehension scores. The average score for each 
item was greater than 3.2 (out of maximum 4), meaning 
the items were easy to understand. The difference for com-
prehension between 18 items was not significant (Fried-
man ANOVA χ2 [N = 134, df = 17] = 27.49, P = 0.051).
Validation study
Men and women were of comparable age (52.0 vs 52.6 
years, P = 0.537) at the time of inclusion but men smoked 
significantly more (43.0 vs 32.2 pack-years, P < 0.001) and 
were more likely to have quit (P = 0.012), although most 
participants were current smokers (85.8%) (Table 1). More 
than half of the participants of both sex (men, 56.4% vs 
women, 56.1%, P = 0.840) had chronic disorders other than 
respiratory and almost half of all participants were on some 
chronic disease treatment (42.7% vs 43.9%, P = 0.562). Men 
had a significantly higher body mass index (27.5 vs 25.4 
kg/m2, P < 0.001) with significantly higher systolic and di-
astolic blood pressure (P = 0.014, P = 0.003, respectively) 
and a comparable heart rate (P = 0.751). Chronic or recur-
ring respiratory symptoms were present in more than 60% 
of participants, with cough/sputum being present in ap-
proximately half of them and wheezing in more than 20%, 
with no significant difference between sexes (P > 0.300 for 
all comparisons). No significant difference was found for 
FEV1 (P = 0.620) and FEV1/FVC ratio (P = 0.066) but men had 
significantly lower FVC (P = 0.001) (Table 1).
Psychometric analyses indicated that the 18-item ques-
tionnaire had a very good internal consistency (Cronbach’s 
alpha = 0.91) and test-retest reliability for a four week pe-
riod (ρc = 0.89, 95% CI 0.85-0.92, Lin’s concordance; r = 0.89, 
95% CI 0.85-0.96, P < 0.001, Pearson correlation).
The item-to-total correlations identified four questions 
whose coefficients were lower than 0.50, and the scores 
of this revised 14-item version of the questionnaire were 
also tested and compared with the scores of the 18-item 
questionnaire.
Internal consistency of the 14-item version was a bit better 
(Cronbach’s alpha = 0.94), with a comparable test-retest re-
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liability for a four week period (ρc = 0.88, 95% CI 0.84-0.91, 
Lin’s concordance; r = 0.88, 95% CI 0.81-0.95, P < 0.001, Pear-
son correlation). The median (IQR) scores of the 18- and 14-
item versions of the MARKO questionnaire, CAT scores, and 
SGRQ scores and subgroup comparisons are presented in 
Table 2. There were no significant differences in the scores 
of both versions for sex (P > 0.200 for both). The correla-
tions of both scores with age were not significant (r <0.02, 
P > 0.800 for both).
We found significant moderate positive correlations of 
MARKO scores with CAT scores of r = 0.69 (95% CI 0.59-
0.79, P < 0.001) and r = 0.63 (95% CI 0.53-0.74, P < 0.001) for 
the 18- and 14-item versions, respectively. Comparable sig-
nificant moderate positive correlations were found for the 
18- and 14-item versions with the individual domains of 
SGRQ (Symptom score: r = 0.69, 95% CI 0.59-0.79, P < 0.001 
and r = 0.59, 95% CI 0.48-0.71, P < 0.001, respectively; Activ-
ity score: r = 0.67, 95% CI 0.57-0.78, P < 0.001 and r = 0.71, 
95% CI 0.61-0.81, P < 0.001, respectively; Impact score: 
r = 0.68, 95% CI 0.58-0.79, P < 0.001 and r = 0.68, 95% CI 0.57-
0.78, P < 0.001, respectively). Strong positive correlations 
were found between MARKO scores and SGRQ total score 
(r = 0.81, 95% CI 0.73-0.89, P < 0.001 for the 18-item version; 
r = 0.80, 95% CI 0.72-0.88, P < 0.001 for the 14-item version).
Although analysis of variance was significant for between 
group comparisons (“healthy” smokers, symptomatic 
smokers, COPD GOLD 1, and COPD GOLD 2) for all HRQoL 
questionnaires (MARKO, CAT, and SGRQ, P < 0.001 for all), 
only the 18-item MARKO questionnaire showed a signifi-
cantly lower median score in “healthy” smokers compared 
to other three groups (M = 7 vs 13 vs 10 vs 18, P < 0.001, 
P = 0.045 and P < 0.001, respectively; Table 2). Post-hoc 
analysis did not show a significant difference between oth-
er three groups (P > 0.200 for all comparisons for all HRQoL 
questionnaires). ROC curve analysis showed an AUC of 
0.753 (95% CI 0.691 to 0.808, P < 0.001) with a sensitivity 
of 71.83% and specificity of 64.24%, PPV 48.57%, and NPV 
82.91% for the MARKO score criterion of ≤10 for “healthy” 
smokers. Using “healthy” smokers as the reference group, 
18-item MARKO questionnaire showed an OR of 1.14 (95% 
CI 1.08 to 1.20) for symptomatic smokers, OR of 1.10 (95% 
CI 1.03 to 1.18) for COPD GOLD 1, and OR of 1.17 (95% CI 
1.09 to 1.26) for COPD GOLD 2 for each additional point on 
the scale (P < 0.001 for all).
tABLe 1. Characteristics of participants recruited in a validation study (N = 224)*†
Characteristics total (N = 224) Men (n = 110) Women (n = 114) P
Age (years)  52.3 ± 6.7  52.0 ± 6.9  52.6 ± 6.4 0.537
Smoking history (pack-years)  37.5 ± 16.7  43.0 ± 17.9  32.2 ± 13.6 <0.001
ex-smokers  32 (14.2)  22 (21.2)  10 (9.0) 0.012
Comorbidities 126 (56.3)  62 (56.4)  64 (56.1) 0.840
Chronic treatment  97 (43.3)  47 (42.7)  50 (43.9) 0.562
Body mass index (kg/m2)  26.4 ± 4.1  27.5 ± 3.9  25.4 ± 4.1 <0.001
Systolic blood pressure (mmhg) 126 ± 15 128 ± 14 123 ± 16 0.014
Diastolic blood pressure (mmhg)  80 ± 9  82 ± 9  78 ± 9 0.003
heart rate (min-1)  80 ± 12  79 ± 13  80 ± 11 0.751
Respiratory symptoms 138 (61.6)  66 (60.0)  72 (63.2) 0.627
wheezing  49 (21.9)  23 (20.9)  26 (22.8) 0.731
cough 114 (50.9)  54 (49.1)  60 (53.1) 0.550
sputum 107 (47.8)  53 (48.2)  54 (47.4) 0.903
night awakenings  16 (7.1)  10 (10.3)   6 (6.3) 0.307
chest pain  25 (11.2)  11 (10.2)  14 (12.6) 0.572
Respiratory sounds
soft  73 (32.6)  43 (39.1)  30 (26.3) 0.027
prolonged expiration  25 (11.2)  13 (11.8)  12 (10.5) 0.949
rhonchi  30 (13.4)  15 (13.6)  15 (13.2) 0.908
Lung function (post bronchodilator)*
FVC (% expected) 109.8 ± 16.9 106.0 ± 15.0 113.4 ± 17.9 0.001
FEV1 (% expected)  99.7 ± 15.2  99.1 ± 14.8 100.2 ± 15.6 0.620
FEV1/FVC (%)  76.0 ± 6.4  75.2 ± 6.7  76.8 ± 6.0 0.066
*FVC – forced vital capacity, FeV1 – forced expiratory volume in 1 second.
†All data are presented as mean±SD or as number (%). Statistical significance for between sex comparisons was tested using t test or χ2-test.
LIFESTYLE RISKS430 Croat Med J. 2016;57:425-33
www.cmj.hr
tABLe 2. Scores for the MARKO questionnaire, COPD Assessment test (CAt) and St’ George Respiratory Questionnaire (SGRQ) accord-
ing to different subgroups*†
MARKO questionnaire CAt SGRQ scores
18-item 14-item score symptom activity impact total
All (N = 224)
Range
11 (7-18.5)
0-44
8 (3.5-13.5)
0-36
8 (4-13)
0-37
14.5 (6.3-31.8)
0-100
18.3 (6-35.5)
0-79.6
3.9 (0-12.4)
0-55.3
12.5 (4.3-21.2)
0-56.5
Sex Men (n = 110) 10 (7-17) 7 (3-13) 8 (4-12) 16.0 (4.6-30.2) 23.2 (6-32.4) 4.2 (0-14.1) 12.9 (4.4-21.8)
Women (n = 114) 13 (6-19) 9 (4-14) 9 (4-14) 13 (7.5-34.4) 17.4 (6-35.5) 3.7 (0-9.5) 11.3 (4.1-20)
P 0.162 0.18 0.147 0.805 0.975 0.361 0.625
Subgroups 
after 
diagnostic
workup
HS (n = 72) 7 (3-11) 5 (2-9) 5 (2-8) 6.3 (0-14.2) 11.2 (0-29.3) 0 (0-4) 5.2 (1.9-13.3)
SS (n = 110) 13 (9-20)II 9 (4-15)II 10 (6-15)II 19.6 (11-37.3)II 23.4 (6-35.6) 6.7 (0-13.4)II 14.7 (6.8-24.1)II
COPD GOLD 1 (n = 23) 10 (8-20)‡ 8 (5-14) 9 (4-12) 11.4 (2.6-28) 20.4 (11.2-29.5) 5.1 (0-17.2) 12.3 (3.8-21.9)
COPD GOLD 2 (n = 19) 18 (10-26)II 13 (7-23)II 11.5 (6.5-18)§ 29.2 (15.1-38.7)§ 23.3 (17.4-47.7) 11.4 (3-20.8)‡ 18.3 (12.1-30.1)§
P <0.001 <0.001 <0.001 0.039 <0.001 <0.001 <0.001
COPD no (n = 182) 11 (6-16) 8 (3-12) 8 (4-13) 14.1 (6.3-31.7) 17.4 (6-35.4) 3.7 (0-10.6) 11.2 (4.1-19.9)
yes (n = 42) 14 (9-24) 10 (5.5-18.5) 9 (5-15) 22.6 (5.4-34.4) 23.3 (12.4-35.8) 7.6 (0-18) 17.2 (7.5-27)
P 0.008 0.015 0.133 0.264 0.226 0.098 0.090
Smoking ex-smokers (n = 32) 10 (6.5-19) 8.5 (4-13.5) 7 (3-12) 6.3 (0-16.6) 29.5 (11.8-35.6) 4.2 (0-12.9) 15.5 (4.8-21.7)
active (n = 192) 11 (7-19) 8 (3-14) 8 (4-14) 16.6 (8.8-34.4) 17.4 (6-32.5) 3.9 (0-12.4) 12.5 (4.4-21.3)
P 0.657 0.697 0.324 0.002 0.054 0.637 0.533
Comorbidities no (n = 98) 10 (6-16) 7.5 (3.5-12) 8 (4-13) 14.8 (6.3-34.4) 17.4 (6-29.5) 3.8 (0-11.4) 12.6 (4.3-17.4)
yes (n = 126) 11 (7-19) 8 (4-15) 8 (4-13) 14.1 (5.1-27.9) 23.3 (6.2-35.5) 4.2 (0-13.3) 12.3 (4.4-22)
P 0.238 0.113 0.943 0.414 0.132 0.527 0.440
Chronic
treatment
no (n = 127) 10 (6-17) 7 (3-12) 8 (4-12) 14.1 (6.3-31.7) 17.1 (6-29.5) 2 (0-10.2) 11 (3.8-17.4)
yes (n = 97) 11 (8-19) 8 (5-15) 9 (5-14) 14.9 (6.3-34.2) 23.5 (11.2-35.6) 6.1 (0-14.3) 14.7 (5.8-22.4)
P 0.085 0.040 0.124 0.908 0.022 0.026 0.026
Respiratory
symptoms
no (n = 86) 7.5 (3-14) 6 (2-10) 5 (2-9) 6.3 (0-14.2) 11.5 (0-29.5) 0 (0-4.2) 5.2 (1.9-14.4)
yes (n = 138) 14 (9-21) 9 (5-15) 10 (6-15) 22.5 (11.1-38) 23.3 (11.2-35.5) 7.2 (0-14.9) 15 (7.9-24.1)
P <0.001 <0.001 <0.001 <0.001 0.013 <0.001 <0.001
Wheezing no (n = 175) 10 (6-15) 7 (3-12) 7 (4-11) 11 (2.3-22.4) 17.1 (6-29.5) 2 (0-9.5) 9 (3.8-17)
yes (n = 49) 19 (13-25) 12 (9-18) 14 (10-18) 34.6 (22.6-45.8) 29.5 (18.5-41.3) 10.3 (4.3-18.1) 21.4 (14.1-27.4)
P <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Chronic/
cough sputum
no (n = 110) 9 (4-14) 6 (3-10) 7 (3-11) 8.9 (0-18.3) 17.1 (6-29.5) 0 (0-7.9) 7.6 (2.5-16.3)
yes (n = 114) 14 (10-22) 9 (5-16) 10 (6-16) 22.9 (11.1-40.5) 23.4 (11.2-35.6) 7.4 (0-15.9) 15.7 (6.9-25.4)
P <0.001 <0.001 <0.001 <0.001 0.017 <0.001 <0.001
Night no (n = 208) 11 (6-18) 8 (4-12) 8 (4-12) 12.2 (6.3-30.2) 18.2 (6.2-35.4) 3.8 (0-10.4) 12.5 (4.4-19.4)
awakenings yes (n = 16) 23 (12-34.5) 15 (8-28.5) 17 (13-25.5) 46.9 (22.9-64.7) 26.5 (12.2-53.6) 20.9 (12.5-
36.6)
27 (21.9-45.7)
P <0.001 0.003 <0.001 <0.001 0.076 <0.001 <0.001
Chest pain no (n = 199) 10 (6-15) 7 (3-12) 8 (4-12) 11.9 (4.4-28) 17.4 (6-29.5) 3.7 (0-10.3) 11.1 (4.1-18.2)
yes (n = 25) 20 (15-27) 16 (11-20) 13 (9-18) 31.7 (15.3-49.4) 41.8 (23.7-53.6) 12.2 (3.6-25.7) 25.3 (15.7-36.5)
P <0.001 <0.001 <0.001 <0.001 <0.001 0.001 <0.001
Fatigue no (n = 160) 9 (4-13) 6 (3-9) 6.5 (3-10) 11.1 (2.6-27.3) 12.2 (0-23.5) 1.8 (0-7.4) 7.7 (3.6-14.7)
yes (n = 64) 19 (14-25) 14.5 (11-20) 13 (8-18) 21.7 (9.6-40.5) 35.8 (23.7-48) 13.7 (7.1-22.9) 23.1 (17-30.1)
P <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Soft noise on
auscultation
no (n = 151) 11 (6-16) 8 (3-12) 8 (4-13) 14.1 (6.6-27.3) 17.4 (6-29.5) 3.8 (0-11.4) 11.7 (4.5-18.6)
yes (n = 73) 11 (6-19) 8 (4-13) 8 (4-13) 11.7 (2.3-34.4) 12.4 (0-35.8) 3.9 (0-15.4) 11.1 (3.6-26)
P 0.786 0.881 0.744 0.745 0.824 0.750 0.916
Prolonged
expiration
no (n = 199) 10 (6-16) 7 (3-12) 8 (4-13) 11.6 (4.5-28) 17.4 (6-35.4) 3.9 (0-11.4) 11.2 (4-19.6)
yes (n = 25) 16 (9-25) 10 (6-21) 9.5 (5.5-14) 21.1 (10.7-34.4) 23.7 (12.4-35.3) 7.4 (0-18.7) 17.1 (5.2-27.4)
P 0.007 0.008 0.194 0.076 0.226 0.122 0.080
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The 14-item MARKO questionnaire, CAT, and SGRQ did not 
show significantly different scores between “healthy” smok-
ers and COPD GOLD 1 subgroups (P > 0.05 for all compari-
sons; Table 2). Also the 18- and 14-item MARKO question-
naires were the only that significantly discriminated COPD 
from non-COPD participants (M = 14 vs 11, P = 0.008; 10 vs 
8, P = 0.015; Table 2). ROC curve analysis for the 18-item 
MARKO questionnaire showed an AUC of 0.634 (95% CI 
0.567 to 0.698, P = 0.004), with a sensitivity of 62.50% and 
specificity of 49.45%, PPV 21.37%, and NPV 85.71% for the 
score criterion of >10 for COPD. With each additional point 
on the scale of the 18-item MARKO questionnaire, the odds 
for COPD diagnosis significantly increased by 5% (OR 1.05, 
95% CI 1.01 to 1.08, P = 0.009). AUC for the 14-item MARKO 
questionnaire was 0.623 (95% CI 0.555 to 0.687, P = 0.010). 
Although the scores for other questionnaires were lower in 
non-COPD participants, these differences were not signifi-
cant (P > 0.09 for all).
Active smokers were significantly different from ex smok-
ers only in the SGRQ symptoms domain (M = 16.6 vs 6.3, 
P = 0.001; Table 2). Having a comorbidity did not produce 
a significantly different score on any of the used question-
naires (P > 0.110), but using a chronic treatment for other 
than respiratory disorder produced a significantly different 
scores for the 14-item MARKO questionnaire (M = 8 vs 7, 
P = 0.040), SGRQ total score (M = 14.7 vs 11, P = 0.026), SGRQ 
activity domain (M = 23.5 vs 17.1, P = 0.022), and SGRQ im-
pact domain (6.1 vs 2, P = 0.026; Table 2).
All four questionnaires significantly discriminated (Table 
2) between the subgroups with or without chronic respi-
ratory symptoms (P < 0.001 for all comparisons), with or 
without wheezing (P < 0.001 for all comparisons), with or 
without chronic cough and sputum (P < 0.001 for all com-
parisons), with or without night awakening (P < 0.01 for all 
comparisons), with or without chest pain (P < 0.001 for all 
comparisons), with or without fatigue (P < 0.001 for all com-
parisons), and with or without rhonchi during auscultation 
of lungs (P < 0.05 for all comparisons). ROC curve analysis 
for the 18-item MARKO questionnaire showed an AUC of 
0.873 (95% CI 0.821 to 0.914, P < 0.001) with a sensitivity 
of 100% and specificity of 47.70%, PPV 44.14%, and NPV 
100% for the score criterion of >8 for fatigue. None of the 
questionnaires (Table 2) significantly discriminated partici-
pants with a soft noise compared to normal noise during 
auscultation (P > 0.740), but the 18- and 14-item MARKO 
questionnaires showed a significantly different scores for 
the prolonged expiration (M = 16 vs 10, P = 0.007; 10 vs 7, 
P = 0.008; respectively). ROC curve analysis for the 18-item 
MARKO questionnaire showed an AUC of 0.667 (95% CI 
0.596 to 0.731, P = 0.004), with a sensitivity of 56.00% and 
specificity of 70.62%, PPV 21.21%, and NPV 91.91% for the 
score criterion of >14 for prolonged expiration.
DISCuSSION
The main result of our initial validation study was that the 
MARKO questionnaire showed expected properties in a 
setup and population of the intended use (8). It was val-
idated for comprehension and had a very good internal 
consistency and test-retest reliability, with high conver-
gent validity correlation with the already validated COPD 
HRQoL questionnaires (SGRQ and CAT). A very important 
finding was that MARKO questionnaire better detected 
early symptoms in smokers than the other two question-
naires, significantly discriminating symptomatic smok-
ers/ex-smokers and COPD patients from “healthy” 
Rhonchi no (n = 194) 10 (6-15.5) 7 (3-12) 8 (4-12) 11.6 (3.6-27.6) 17.4 (6-35.5) 3.8 (0-10.6) 11.3 (3.8-19.6)
yes (n = 30) 18.5 (11-25) 12 (7-19) 12.5 (5.5-17) 23.8 (12.2-42.9) 18.5 (6-35.9) 10.3 (0-18.7) 13.7 (8-27.6)
P <0.001 0.004 0.021 0.001 0.581 0.025 0.031
*hS – “healthy” smokers/ex-smokers, SS – symptomatic smokers/ex-smokers, COPD GOLD 1 – participants diagnosed with chronic obstructive 
pulmonary disease (COPD) with tiffeneau index <0.7 and forced expiratory volume in 1 second (FeV1)>80% predicted, COPD GOLD 2 – participants 
diagnosed as COPD with tiffeneau index <0.7 and FeV1<80% and ≥50% predicted.
†All data are presented as median and interquartile range (IQR) and as range for the overall scores. Statistical significance for subgroups compari-
sons was tested using Mann-Whitney u test for all independent variables except for 4 subgroups according to diagnosis after the diagnostic workup 
that was tested using Kruskal-Wallis ANOVA.
‡Significantly different from hS (post-hoc analysis): P < 0.05.
§Significantly different from hS (post-hoc analysis): P < 0.01.
IISignificantly different from hS (post-hoc analysis): P < 0.001.
tABLe 2. Continued. Scores for the MARKO questionnaire, COPD Assessment test (CAt) and St’ George Respiratory Questionnaire 
(SGRQ) according to different subgroups*†
MARKO questionnaire CAt SGRQ scores
18-item 14-item score symptom activity impact total
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smokers/ex-smokers. Almost no differences were seen be-
tween the 14- and 18- item versions of the MARKO ques-
tionnaire, with a significantly better result for the 18-item 
version only regarding discriminating other subgroups 
from “healthy” smokers/ex-smokers. These results repre-
sent the first step and a prerequisite for further validation 
of the MARKO questionnaire regarding its predictive pow-
er as an early marker of future development of COPD (as 
a single marker or in combination) that can be used for 
screening in a primary care setting.
Population screening for COPD is not a recommended 
strategy but early diagnosis in a population at risk is high-
ly recommended because of a high proportion of undi-
agnosed or late diagnosed COPD associated with high 
morbidity (1,2,9). Several approaches for use in primary 
care were tested but only to make an early diagnosis of 
the already present COPD (10). The MARKO questionnaire 
showed comparable results regarding the diagnostic po-
tential for COPD in a primary care setting to the results of a 
meta-analysis of COPD Diagnostic Questionnaire (CDQ) by 
Haroon et al (10). However, rather than constructing a di-
agnostic questionnaire for COPD, our aim was to construct 
a questionnaire that could identify early changes in HRQoL 
in smokers leading to subsequent development of COPD. 
Having such an instrument could help in starting second-
ary prevention earlier or starting an early intervention. In 
regard to this aim, the MARKO questionnaire showed a 
higher sensitivity for early symptoms of future possible 
COPD than SGRQ or CAT, with high convergent validity 
correlation with these already validated COPD health sta-
tus questionnaires. This high convergent validity correla-
tion is also important because it shows specificity for respi-
ratory disorders and could probably mean that it could be 
associated with already known features of CAT and SGRQ, 
showing association with many facets of COPD, like under-
lying inflammation, airway limitation, breathlessness, pro-
gression of disease, morbidity, and mortality (11-15). On 
the other hand, at least for the 18-item version, the results 
were not influenced by common comorbidities and con-
comitant treatment. In the systematic review by Haroon et 
al, the major risk for bias when evaluating the question-
naires and handheld flow meters for screening purposes 
was inadequate blinding between index tests and spirom-
etry, which was not the case in our study (10).
Further validation is expected after a follow-up of the co-
hort of smokers recruited into the MARKO study, when 
the potential of this tool to predict future develop-
ment of COPD in smokers/ex-smokers at risk for 
COPD will be evaluated (as a single tool or combined with 
other markers).
Based on basic psychometric analyses and high conver-
gent validity correlation with already validated HRQoL 
questionnaires, the newly developed MARKO question-
naire was shown to be a reliable self-administered short 
health status assessment tool. It had a better discriminating 
power for early changes associated with smoking suscepti-
bility than other two questionnaires (CAT and SGRQ), thus 
being in accordance with the newest recommendations as 
a first step in making an early diagnosis. These properties 
will be tested prospectively in an ongoing cohort study to 
evaluate the predictive power of the MARKO questionnaire 
to identify individuals who will develop COPD among indi-
viduals at risk.
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